Biotechnology Assets S.A. Cash Flow Conversion Efficiency
Biotechnology Assets S.A. cash flow conversion efficiency. Based on the latest financial reports, Biotechnology Assets S.A. (BST) has a cash flow conversion efficiency ratio of 0.102x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€658.13K ≈ $769.43K USD) by net assets (€6.45 Million ≈ $7.54 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Biotechnology Assets S.A. (2014–2024)
Cash flow conversion efficiency of Biotechnology Assets S.A. from 2014 to 2024. This chart illustrates how Biotechnology Assets S.A.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View Biotechnology Assets S.A. (BST) stock price for real-time trading data and today's change.
Biotechnology Assets S.A. Cash Flow Conversion Ratio Explained
Biotechnology Assets S.A. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Biotechnology Assets S.A. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Biotechnology Assets S.A. ranked by their cash flow conversion efficiency. Also see market cap of Biotechnology Assets S.A. for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quantum BioPharma Ltd.
NASDAQ:QNTM
|
-0.286x |
|
The Hain Celestial Group Inc
NASDAQ:HAIN
|
0.178x |
|
Vesuvius PLC
LSE:VSVS
|
0.057x |
|
Bionano Genomics Inc
NASDAQ:BNGO
|
-0.148x |
|
Lena Lighting S.A.
WAR:LEN
|
-0.024x |
|
Anebulo Pharmaceuticals Inc
NASDAQ:ANEB
|
-0.165x |
|
Finlay Minerals Ltd
V:FYL
|
0.037x |
|
Steel City Securities Limited
NSE:STEELCITY
|
0.025x |
Annual Cash Flow Conversion Efficiency for Biotechnology Assets S.A. (2014–2024)
The table below shows the annual cash flow conversion efficiency of Biotechnology Assets S.A. from 2014 to 2024. Review BST cash flow after capex ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | €6.61 Million ≈ $7.73 Million |
€-73.85K ≈ $-86.34K |
-0.011x | -252.87% |
| 2023-12-31 | €6.53 Million ≈ $7.64 Million |
€47.74K ≈ $55.81K |
0.007x | +101.63% |
| 2022-12-31 | €3.87 Million ≈ $4.53 Million |
€-1.73 Million ≈ $-2.03 Million |
-0.447x | -29.25% |
| 2021-12-31 | €4.34 Million ≈ $5.07 Million |
€-1.50 Million ≈ $-1.76 Million |
-0.346x | -115.13% |
| 2020-12-31 | €3.84 Million ≈ $4.49 Million |
€8.79 Million ≈ $10.28 Million |
2.288x | +214.10% |
| 2019-12-31 | €7.56 Million ≈ $8.84 Million |
€-15.16 Million ≈ $-17.72 Million |
-2.005x | -226.35% |
| 2018-12-31 | €21.19 Million ≈ $24.78 Million |
€-13.02 Million ≈ $-15.23 Million |
-0.614x | -2410.54% |
| 2017-12-31 | €8.03 Million ≈ $9.38 Million |
€213.49K ≈ $249.59K |
0.027x | -92.21% |
| 2016-12-31 | €7.96 Million ≈ $9.30 Million |
€2.71 Million ≈ $3.17 Million |
0.341x | +1533.30% |
| 2015-12-31 | €7.57 Million ≈ $8.85 Million |
€158.16K ≈ $184.90K |
0.021x | +152.79% |
| 2014-12-31 | €7.68 Million ≈ $8.97 Million |
€-303.79K ≈ $-355.16K |
-0.040x | -- |
About Biotechnology Assets S.A.
Biotechnology Assets, S.A. develops and markets biotechnological assets for applications in the biopharmaceutical, agrochemical, cosmetic, veterinary, and chemical industries in Spain and internationally. It offers SPLITTERA, a protein engineering tool that allows the conjugation of proteins through the formation of new peptide bonds; universal switchable split-chimeric antigen receptor (CAR); VA… Read more